Pulmonary Embolism Market Size, Growth, Trends and Research Analysis by TBRC

Posted by ramacharitbrc on April 2nd, 2024

Overview and Scope

A pulmonary embolism is a blockage in the pulmonary artery, which transports blood from the heart to the lungs. It causes the clot of blood that has gone to the lungs from another area of the body, most commonly the legs, which causes blockage. The symptoms of pulmonary embolism might range from abrupt shortness of breath to chest pain, coughing up blood or bloody mucus and others, depending on the severity of the clot.

Sizing and Forecast

The pulmonary embolism market size has grown rapidly in recent years. It will grow from .81 billion in 2023 to .03 billion in 2024 at a compound annual growth rate (CAGR) of 11.9%.  The  growth in the historic period can be attributed to anticoagulant therapies, research and clinical trials, pulmonary embolism awareness, vte prophylaxis.

The pulmonary embolism market size is expected to see rapid growth in the next few years. It will grow to .2 billion in 2028 at a compound annual growth rate (CAGR) of 12.1%.  The growth in the forecast period can be attributed to targeted therapies, telemedicine and remote monitoring, health equity initiatives, global health initiatives. Major trends in the forecast period include artificial intelligence in diagnosis, novel anticoagulants, pulmonary embolism response teams, patient-centered care.

To access more details regarding this report, visit the link:


Segmentation & Regional Insights

The pulmonary embolism market covered in this report is segmented –

1) By Treatment: Medications; Mechanical Devices; Other Treatments

2) By Diagnosis: Chest X-Ray; Electrocardiogram (ECG); Magnetic Resonance Imaging (MRI); Computed Tomography Scan; Pulmonary Angiography; Venography; Venous Ultrasound; D-Dimer Test; Other Diagnosis

3) By Symptoms: Shortness Of Breath; Chest Pain; Cough; Irregular Heartbeat; Dizziness; Fever; Cyanosis; Other Symptoms

4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels

5) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users

North America was the largest region in the pulmonary embolism market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pulmonary embolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:


Major Driver Impacting Market Growth

The increasing prevalence of blood clots is expected to propel the growth of the pulmonary embolism market going forward. A blood clot, also known as a thrombus, is a gel-like or semisolid mass that forms within a blood vessel. Blood clots raise the risk of pulmonary embolism by obstructing blood flow to the lungs. This blood clot causes blockage, typically in the legs' deep veins, thus increasing the risk of pulmonary embolism. For instance, in April 2022, according to an article published by Gavi, the Vaccine Alliance, an international organization created to improve access to new and underused vaccines for children, stated that in the 30 days following exposure to COVID-19, scientists discovered a 33-fold rise in the chance of potentially fatal clots in the lungs and a five-fold increase in the risk of deep vein thrombosis. Therefore, an increasing prevalence of blood clots is driving the growth of the pulmonary embolism market.

Key Industry Players

Major players in the pulmonary embolism market are  Pfizer Inc., Johnson and Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co.Inc., Novartis AG, Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, GSK PLC, Abbott Laboratories, AstraZeneca PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Mitsubishi Tanabe Pharma Corporation, Genentech Inc., Hikma Pharmaceuticals PLC, Aspen Pharmacare Holdings Limited, Nippon Shinyaku Co. Ltd., Penumbra Inc., Fresenius Kabi AG, Inari Medical Inc., AngioDynamics Inc., Otsuka Pharmaceutical Co. Ltd.

The pulmonary embolism market report table of contents includes:

1. Executive Summary

2. Market Characteristics

3. Market Trends And Strategies

4. Impact Of COVID-19

5. Market Size And Growth

6. Segmentation

7. Regional And Country Analysis


27. Competitive Landscape And Company Profiles

28. Key Mergers And Acquisitions

29. Future Outlook and Potential Analysis

Like it? Share it!


About the Author

Joined: July 1st, 2020
Articles Posted: 1,960

More by this author